{"disease":{"id":"egfr-mutated-non-small-cell-lung-carcinoma","name":"egfr mutated non small cell lung carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04538378","title":"Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}